Avantor Faces Class Action for Misrepresentation; Investors May Claim Compensation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy AVTR?
Source: Globenewswire
- Lawsuit Background: Rosen Law Firm reminds investors who purchased Avantor (NYSE: AVTR) common stock between March 5, 2024, and October 28, 2025, that December 29 is the deadline to apply as lead plaintiff, indicating potential investor losses.
- Compensation Mechanism: Investors who bought shares during this period may claim compensation through a contingency fee arrangement, which alleviates financial burdens and encourages more affected parties to participate in the lawsuit.
- Law Firm Advantages: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in such cases.
- Case Details: The lawsuit alleges that Avantor misrepresented its competitive positioning and failed to disclose negative impacts from increased competition, leading to investor losses when the truth emerged, highlighting the importance of transparency and corporate governance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 7.840
Low
8.00
Averages
11.67
High
16.00
Current: 7.840
Low
8.00
Averages
11.67
High
16.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avantor CFO R. Brent Jones to Depart by June 2026
- Executive Departure: Avantor announced that CFO R. Brent Jones will leave the company by June 24, 2026, potentially leading to uncertainty in financial strategy and operations, which may impact investor confidence.
- Interim Succession Plan: To ensure a smooth transition, Senior Vice President and Chief Accounting Officer Steve Eck will serve as interim CFO upon Jones's departure; Eck has been CAO since 2019 and brings extensive financial management experience.
- Financial Outlook Adjustment: Avantor projects organic revenue growth of negative 2.5% to negative 0.5% for 2026, reflecting challenges in its revival program and business resegmentation, which could affect future profitability and market performance.
- Market Environment Impact: Amid disruptions in the Middle East, Avantor is considered one of the oversold mid-cap healthcare stocks on Wall Street, indicating increasing market concerns regarding its future performance.
See More
Avantor CFO R. Brent Jones to Step Down by June 24
- Executive Change: Avantor's CFO R. Brent Jones will step down by June 24, marking a significant shift in the company's leadership that may affect investor confidence in its financial stability.
- Interim Appointment: The company has appointed Steve Eck, senior vice president and chief accounting officer, as interim CFO; Eck has been responsible for financial reporting and internal controls since 2019, ensuring continuity in financial management during the transition.
- Successor Search: Avantor has initiated a search for a suitable candidate to replace Jones, a process that could influence the company's strategic direction and future financial decisions.
- Market Reaction: Executive changes often trigger market uncertainty, prompting investors to monitor the company's financial performance under new leadership and its potential impact on stock prices.
See More
Circumference Group Acquires New Position in Avantor
- New Position Disclosure: Circumference Group disclosed a new position in Avantor by acquiring 305,000 shares worth $3.5 million in Q4 2026, reflecting confidence in the company despite a 54% decline in its stock price over the past year.
- Asset Allocation Insight: This acquisition represents 3.77% of Circumference Group's 13F reportable assets, indicating a strategic positioning within a diversified portfolio, particularly in light of ongoing demand in the biopharma and advanced technology sectors.
- Company Financial Overview: Avantor reported over $6.5 billion in revenue for the full year 2025, with quarterly sales down 1%, yet adjusted EBITDA exceeding $1 billion highlights its potential for stable cash flow, especially with management's “Revival” program underway.
- Market Outlook Analysis: The stable demand for lab consumables and the management's focus on execution improvements may position Avantor as a strong cash generator in the future, attracting long-term investors' interest amidst ongoing production workflow needs.
See More
Circumference Group Acquires Shares in Avantor
- New Investment Position: Circumference Group initiated a new position in Avantor by acquiring 305,000 shares worth $3.5 million during Q4 2026, reflecting confidence in the company despite its 3.77% portfolio allocation.
- Financial Performance Review: Avantor reported a 1% decline in quarterly sales to $1.66 billion, with full-year revenue exceeding $6.5 billion, but faced a full-year loss due to one-time charges, indicating pressure on profitability.
- Management Revival Program: Avantor is implementing a 'Revival' program aimed at addressing execution and cost structure issues, focusing on go-to-market strategies and supply chain improvements, which could help restore margins and enhance cash flow if successful.
- Market Position Advantage: Unlike high-growth biotech firms, Avantor benefits from stable demand for lab consumables and production workflows, making it crucial for long-term investors to monitor its ability to recover margins without sacrificing volume.
See More
Eversept Partners Increases Stake in Avantor
- Share Increase: Eversept Partners disclosed a purchase of 2,252,202 shares of Avantor in Q4 2025, valued at approximately $27.72 million, indicating confidence in the company's future despite a 50% decline in stock price over the past year.
- Holding Status: Following the acquisition, Eversept's total holdings in Avantor reached 3,176,644 shares worth $36.40 million, representing 1.83% of its U.S. equity portfolio, though it remains outside the top five positions.
- Financial Performance: Avantor reported a revenue of $6.55 billion for 2025, a 3% decline year-over-year, alongside a net loss of $530.2 million, with the CEO emphasizing the importance of the
See More
Johnson Fistel Investigates Executive Liability for Multiple Companies
- Shareholder Rights Investigation: Johnson Fistel is investigating potential breaches of fiduciary duty by executives at Avantor, Baxter, Biogen, and CarMax, which may lead shareholders to seek corporate governance reforms and fund recovery.
- Avantor Allegations: A lawsuit against Avantor claims that executives failed to disclose a decline in competitive positioning and negative competitive impacts, leading to shareholder misconceptions about the company's prospects, potentially affecting its stock price.
- Baxter Product Defects: Baxter's Novum LVP product is alleged to have systemic defects that pose serious risks to patients, and the company's inadequate response to these defects may result in significant legal and financial repercussions.
- Biogen Transparency Issues: Biogen is accused of overstating its efforts to enhance transparency and compliance controls, failing to disclose improper conduct in foreign operations, which could lead to regulatory scrutiny and reputational harm.
See More
Avantor CFO R. Brent Jones to Depart by June 2026
- Executive Departure: Avantor announced that CFO R. Brent Jones will leave the company by June 24, 2026, potentially leading to uncertainty in financial strategy and operations, which may impact investor confidence.
- Interim Succession Plan: To ensure a smooth transition, Senior Vice President and Chief Accounting Officer Steve Eck will serve as interim CFO upon Jones's departure; Eck has been CAO since 2019 and brings extensive financial management experience.
- Financial Outlook Adjustment: Avantor projects organic revenue growth of negative 2.5% to negative 0.5% for 2026, reflecting challenges in its revival program and business resegmentation, which could affect future profitability and market performance.
- Market Environment Impact: Amid disruptions in the Middle East, Avantor is considered one of the oversold mid-cap healthcare stocks on Wall Street, indicating increasing market concerns regarding its future performance.
See More
Avantor CFO R. Brent Jones to Step Down by June 24
- Executive Change: Avantor's CFO R. Brent Jones will step down by June 24, marking a significant shift in the company's leadership that may affect investor confidence in its financial stability.
- Interim Appointment: The company has appointed Steve Eck, senior vice president and chief accounting officer, as interim CFO; Eck has been responsible for financial reporting and internal controls since 2019, ensuring continuity in financial management during the transition.
- Successor Search: Avantor has initiated a search for a suitable candidate to replace Jones, a process that could influence the company's strategic direction and future financial decisions.
- Market Reaction: Executive changes often trigger market uncertainty, prompting investors to monitor the company's financial performance under new leadership and its potential impact on stock prices.
See More
Circumference Group Acquires New Position in Avantor
- New Position Disclosure: Circumference Group disclosed a new position in Avantor by acquiring 305,000 shares worth $3.5 million in Q4 2026, reflecting confidence in the company despite a 54% decline in its stock price over the past year.
- Asset Allocation Insight: This acquisition represents 3.77% of Circumference Group's 13F reportable assets, indicating a strategic positioning within a diversified portfolio, particularly in light of ongoing demand in the biopharma and advanced technology sectors.
- Company Financial Overview: Avantor reported over $6.5 billion in revenue for the full year 2025, with quarterly sales down 1%, yet adjusted EBITDA exceeding $1 billion highlights its potential for stable cash flow, especially with management's “Revival” program underway.
- Market Outlook Analysis: The stable demand for lab consumables and the management's focus on execution improvements may position Avantor as a strong cash generator in the future, attracting long-term investors' interest amidst ongoing production workflow needs.
See More
Circumference Group Acquires Shares in Avantor
- New Investment Position: Circumference Group initiated a new position in Avantor by acquiring 305,000 shares worth $3.5 million during Q4 2026, reflecting confidence in the company despite its 3.77% portfolio allocation.
- Financial Performance Review: Avantor reported a 1% decline in quarterly sales to $1.66 billion, with full-year revenue exceeding $6.5 billion, but faced a full-year loss due to one-time charges, indicating pressure on profitability.
- Management Revival Program: Avantor is implementing a 'Revival' program aimed at addressing execution and cost structure issues, focusing on go-to-market strategies and supply chain improvements, which could help restore margins and enhance cash flow if successful.
- Market Position Advantage: Unlike high-growth biotech firms, Avantor benefits from stable demand for lab consumables and production workflows, making it crucial for long-term investors to monitor its ability to recover margins without sacrificing volume.
See More
Eversept Partners Increases Stake in Avantor
- Share Increase: Eversept Partners disclosed a purchase of 2,252,202 shares of Avantor in Q4 2025, valued at approximately $27.72 million, indicating confidence in the company's future despite a 50% decline in stock price over the past year.
- Holding Status: Following the acquisition, Eversept's total holdings in Avantor reached 3,176,644 shares worth $36.40 million, representing 1.83% of its U.S. equity portfolio, though it remains outside the top five positions.
- Financial Performance: Avantor reported a revenue of $6.55 billion for 2025, a 3% decline year-over-year, alongside a net loss of $530.2 million, with the CEO emphasizing the importance of the
See More
Johnson Fistel Investigates Executive Liability for Multiple Companies
- Shareholder Rights Investigation: Johnson Fistel is investigating potential breaches of fiduciary duty by executives at Avantor, Baxter, Biogen, and CarMax, which may lead shareholders to seek corporate governance reforms and fund recovery.
- Avantor Allegations: A lawsuit against Avantor claims that executives failed to disclose a decline in competitive positioning and negative competitive impacts, leading to shareholder misconceptions about the company's prospects, potentially affecting its stock price.
- Baxter Product Defects: Baxter's Novum LVP product is alleged to have systemic defects that pose serious risks to patients, and the company's inadequate response to these defects may result in significant legal and financial repercussions.
- Biogen Transparency Issues: Biogen is accused of overstating its efforts to enhance transparency and compliance controls, failing to disclose improper conduct in foreign operations, which could lead to regulatory scrutiny and reputational harm.
See More
